

EMA/245846/2021

European Medicines Agency decision P/0221/2021

of 9 June 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for bamlanivimab (EMEA-002952-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0221/2021

of 9 June 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for bamlanivimab (EMA-002952-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Eli Lilly and Company Limited on 18 January 2021 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 April 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for bamlanivimab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for bamlanivimab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, Bracknell, RG12 1PU – Berkshire, United Kingdom.

EMA/PDCO/81779/2021 **Corr**

Amsterdam, 23 April 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-002952-PIP01-21

Scope of the application

Active substance(s):

Bamlanivimab

Condition(s):

Treatment of Coronavirus disease 2019 (COVID-19)

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Eli Lilly and Company Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Eli Lilly and Company Limited submitted for agreement to the European Medicines Agency on 18 January 2021 an application for a paediatric investigation plan for the above-mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 22 February 2021.

Supplementary information was provided by the applicant on 19 March 2021. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
 - to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of Coronavirus disease 2019 (COVID-19)

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with COVID-19 who are at risk of progressing to severe disease.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 1 (J2W-MC-PYAB) Randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of bamlanivimab in combination with etesevimab for the treatment of adolescents (and adults) with mild or moderate COVID-19, who are at increased risk of adverse outcomes and severe COVID-19. Study 2 (J2W-MC-PYAB Addendum 2) Multicentre, single arm, open-label study to evaluate pharmacokinetics (PK) and safety of bamlanivimab and etesevimab in children from birth to less than 18 years of age with mild or moderate COVID-19 who are at increased risk of adverse outcomes and severe COVID-19.

Extrapolation, modelling and simulation studies	2	Study 3 PopPK model for bamlanivimab and etesevimab dosing predictions and confirmation in paediatric patients from 32 weeks of gestational and 1.5 kg of weight to less than 18 years of age. Study 4 Extrapolation analyses to support efficacy and safety assumptions for bamlamivimab in combination with etesevimab in the paediatric population from 32 weeks gestational age to less than 18 years of age with mild to moderate COVID-19 at risk of developing severe disease from adult patients with mild to moderate COVID-19 at risk of developing severe disease.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By November 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes